Page 2 - Nasdaq Jspr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase...

Cantor Fitzgerald restated their overweight rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a report issued on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. JSPR has been the topic of a number of other research reports. Credit Suisse Group restated an outperform rating and set a […]

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and Avalon GloboCare (NASDAQ:ALBT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Profitability This table compares Jasper Therapeutics and […]

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 1,010,000 shares, a growth of 19.5% from the July 15th total of 845,500 shares. Based on an average daily volume of 304,400 shares, the short-interest ratio […]

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 861,500 shares, a decline of 18.0% from the May 15th total of 1,050,000 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average […]